Academic Journal
Q1Biomedicine & Pharmacotherapy
About Biomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy is a scholarly journal published by Elsevier Masson s.r.l.. SCImago 2025 places it in Q1 with an SJR of 2.074 and an H-index of 196.
Its listed coverage is 1982-2026 and its research categories include Medicine (miscellaneous) (Q1); Pharmacology (Q1). The 2025 dataset reports 1039 documents and 49563 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Cancer-related molecular mechanisms research, MicroRNA in disease regulation, Circular RNAs in diseases, RNA modifications and cancer, Autophagy in Disease and Therapy, Liver Disease Diagnosis and Treatment.
Recent Research Articles
Latest publications matched automatically by ISSN.
A hypothesis-driven perspective on GLP-1R-β-catenin pathway crosstalk in astrocyte plasticity and endogenous neural repair
Sudichhya Tamrakar, Laurence S. Pe, Jiraporn Panmanee, Jenq-Lin Yang et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119946Research progress on plant-derived exosome-like nanovesicles in regulating and promoting tissue repair
Junrui Li, Xuhao Ji, Yan Xue, Jiabing Shen et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119936Pathogen-informed therapeutic design: Translating host-control functions into pharmacological strategies
Seong Jae Kim, Seonggyu Lim, Chul-Su Yang
2026-11 · DOI: 10.1016/j.biopha.2026.119932Pterygium pathobiology and therapeutic evolution: Integrating mechanistic insights with pharmacological strategies to curb recurrence and advance beyond surgery
Ying Huang, Yingping Deng, Jing Tang, Juan Wang et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119929Development and characterization of a doxorubicin-resistant triple-negative breast cancer spheroid model for drug screening purposes
Viwe Fokazi, Beynon Abrahams, Mamello Sekhoacha, Alandi van Niekerk et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119933Discovery of natural product antagonists for the P2X7 receptor through virtual screening
Natiele Carla da Silva Ferreira, Lauro Miranda Lima, Nicole de Menezes Macedo, Esther dos Santos Campos et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119928Immunopeptidomics-guided cancer vaccine design: Advances, challenges, and emerging opportunities
Mohammad Mahdi Behzadifar, Mahshid Shadkam, Saba Kazemi, Elahe Mirsamiei et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119926Natural product-derived compounds modulating STAT3 signaling in prostate cancer: Mechanistic insights and therapeutic potential
Yikun Feng, Danming Liu, Chen Gu, Tian Zhou et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119935Non-clinical safety evaluation of coenzyme I (NAD⁺): A GLP-compliant systematic study
Jingliang Gu, Jie Xu, Shijun Yang, Yuyang Qiu et al.
2026-11 · DOI: 10.1016/j.biopha.2026.119934Adjunctive nutraceutical strategies in ulcerative colitis: From molecular pathways to clinical outcomes
Carlo Caputo, Azzurra Chiara De Maio, Angela Lombardi, Rossella Sperlongano et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119855Redox remodeling of perivascular adipose tissue in vascular aging
Yun-Xi Liu, Zhen-Rong Chen, Xiu-Heng Wang, Hui-Yi Xie et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119856The peptide Ac2–26 preserves mitochondrial function and neuronal survival in human retinal cells and organoids under hyperglycemic and inflammatory stress
Rafael André da Silva, Shama Parween, Anna Howell, Sydney Hayden et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119849Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma
Raheleh Roudi, Giovanni Marco Saladino, Iryna Vasyliv, Laura Pisani et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119846Total glucosides of paeony ameliorate cognitive impairment by promoting ketogenesis and modulating Glu-AMPAR signaling
Guanhua Hu, Shuqing Gong, Siyu Yan, Liyang Rong et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119851Retraction notice to "Corrigendum to “Mechanism of chromium-induced toxicity in lungs, liver, and kidney and their ameliorative agents” [Biomed. Pharmacother. 151, July 2022, 113119]" [Biomedicine & Pharmacotherapy 181 (2024) 117629]
Rituraj Chakraborty, Kaviyarasi Renu, Mohamed Ahmed Eladl, Mohamed El-Sherbiny et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119878Corrigendum to “Brazilin reduces toxic iron species and oxidative damage in iron-loaded β-thalassemic mice” [Biomed. Pharmacother. 203 (2026), 119886]
Somjintana Taveepanich, Ruttiya Thongrung, Wanwisa Suwannaloet, Suthankamon Khrongyut et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119923Fibroblast activation protein-α in liver fibrosis and hepatocarcinogenesis: Stromal remodeling, molecular imaging, and theranostic targeting
Peng An, Longlong Wu, Rong Wang
2026-10 · DOI: 10.1016/j.biopha.2026.119883Monophosphoryl lipid A, the Toll-like receptor 4 agonist, mitigates acute radiation syndrome via hematopoietic stem cells regeneration
Hyun Jung Ji, Yeongkag Kwon, Joon Hwa Lee, Ki Bum Ahn et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119931PLGA nanoparticles for the delivery of antimicrobial peptides in a polymicrobial sepsis model
Bruno Amorim-Carmo, Emanuell Santos-Silva, Alessandra Daniele-Silva, Adriana M.S. Parente et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119927Albumin surface and interface engineering of non-albumin nanoparticles in cancer nanomedicine: A critical review
Hanan Mohammad, Maher Darwish, Gábor Katona, Ildikó Csóka et al.
2026-10 · DOI: 10.1016/j.biopha.2026.119907Reviews
Community Reviews
Version History
September 8, 2026 at 12:08 am
September 8, 2026